



ASX release

31 October 2008

AtCor to target specialists with lightweight SphygmoCor

AtCor Medical (ASX:ACG), the developer and marketer of the SphygmoCor[®] system which measures central blood pressures and arterial stiffness non-invasively, today announced that it will introduce portable SphygmoCor systems in early November. The new systems will be approximately one-quarter the size and weight of the company's first-generation systems, and are designed to spearhead AtCor Medical's push into the \$US500 million global specialist clinical market.

The lightweight, portable SphygmoCor systems assist evaluation of cardiovascular status and management of patient care by medical specialists, particularly cardiologists, hypertension specialists, nephrologists and endocrinologists. The new systems have a smaller footprint than an average laptop, and can be conveniently used in clinical settings such as hospital bedsides, clinical examination rooms, emergency medical theatres and mobile screening vans.

Duncan Ross, CEO of AtCor Medical, said: "In the United States our sales of systems intended for clinical use, rather than for research or pharmaceutical clinical trials, grew by over 50 per cent in FY2008. The lightweight SphygmoCor retains all the features of the earlier model, and adds heart rate variability testing. These portable systems will allow clinicians to perform central blood pressure assessments wherever they treat their patients. The technology has been enhanced to attract specialists that wanted smaller, easier-to-use systems."

SphygmoCor[®] CP, SphygmoCor[®] CPV and SphygmoCor[®] CPVH systems will be unveiled in the United States at Renal Week 2008, the annual scientific meeting of the American Society of Nephrology (November 6-8) and the American Heart Association Scientific Sessions (November 9-12). The new systems have received US FDA 510k, CE Mark and TGA clearance.

AtCor Medical's SphygmoCor is considered to be the gold standard for measuring central blood pressure non-invasively, and has been featured in more than 400 peer-reviewed publications. Central blood pressure is the actual blood pressure at the heart, rather than approximate blood pressure based on measurement at the arm. The company has a worldwide installed base of over 1700 systems, including 13 of the United States' 17 best hospitals according to the 2007 News & World Report 'honor roll'.

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 1,700 SphygmoCor® systems are currently in use worldwide at major medical institutions research institutions and in various clinical trials with leading pharmaceutical companies, and the company's technology have been featured in over 400 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au